Gynecol Oncol by Bristow, Robert E. et al.
Spatial Analysis of Adherence to Treatment Guidelines for
Advanced-Stage Ovarian Cancer and the Impact of Race and
Socioeconomic Status
Robert E. Bristowa, Jenny Changb, Argyrios Ziogasb, Hoda Anton-Culverb, and Veronica M.
Vieira, DScb
aDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology University of
California, Irvine-Medical Center, Orange, CA
bDepartment of Epidemiology University of California, Irvine, Irvine, CA
Abstract
OBJECTIVE—To determine the impact of geographic location on advanced-stage ovarian cancer
care adherence to National Comprehensive Cancer Network (NCCN) guidelines in relation to race
and socioeconomic status (SES).
METHODS—Patients diagnosed with Stage IIIC/IV epithelial ovarian cancer (1/1/96-12/31/06)
were identified from the California Cancer Registry. Generalized additive models were created to
assess the effect of spatial distributions of geographic location, proximity to a high-volume
hospital (≥20 cases/year), distance travelled to receive care, race, and SES on adherence to NCCN
guidelines, with simultaneous smoothing of geographic location and adjustment for confounding
variables. Disparities in geographic predictors of treatment adherence were analyzed with the χ2
test for equality of proportions.
RESULTS—Of the 11,770 patients identified, 45.4% were treated according to NCCN
guidelines. Black race (OR=1.49, 95%CI=1.21-1.83), low-SES (OR=1.46, 95%CI=1.24-1.72), and
geographic location ≥80km/50mi from a high-volume hospital (OR=1.88, 95%CI=1.61-2.19) were
independently associated with an increased risk of non-adherent care, while high-volume hospital
treatment (OR=0.59, 95%CI=0.53-0.66) and travel distance to receive care ≥32km/20mi
(OR=0.80, 95%CI=0.69-0.92) were independently protective. SES was inversely associated with
location ≥80km/50mi from a high-volume hospital, ranging from 6.3% (high-SES) to 33.0% (low-
SES) (p<0.0001). White patients were significantly more likely to travel ≥32km/20mi to receive
care (21.8%) compared to Blacks (14.4%), Hispanics (15.9%), and Asian/Pacific Islanders
(15.5%) (p<0.0001).
CONCLUSION—Geographic proximity to a high-volume hospital and travel distance to receive
treatment are independently associated with NCCN guideline adherent care for advanced-stage
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ovarian cancer. Geographic barriers to standard ovarian cancer treatment disproportionately affect
racial minorities and women of low-SES.
INTRODUCTION
In the United States, more than 22,000 new cases of ovarian cancer are diagnosed annually,
with over 14,000 disease-related deaths [1]. Recently, adherence to National Comprehensive
Cancer Network (NCCN) treatment guidelines for ovarian cancer has been validated as
correlating with improved disease-specific survival and suggested as a viable process
measure of quality cancer care [2]. Improving adherence to evidence-based processes that
improve survival has been championed as a key requirement for improving the quality of
ovarian cancer care [3]. Race, poverty level, and insurance status have been identified as
independent predictors of both an increased likelihood of nonstandard treatment and worse
survival [4-9].
The U.S. Department of Health and Human Services has targeted disparities in access to
health care as the centerpiece of the Healthy People 2020 campaign [10]. For ovarian
cancer, perhaps more so than any other gynecologic malignancy, improving survival
outcomes for all segments of the population hinges upon universal access to expert care and
the administration of effective contemporary treatment programs [11-15]. While racial
minorities and the socioeconomically disadvantaged are confronted with multiple barriers to
appropriate care, the potential contribution of geography to disparities in ovarian cancer
treatment has not been widely explored. The objective of the current study was to determine
the impact of geographic location on adherence to NCCN treatment guidelines for
advanced-stage ovarian cancer care in relation to race and socioeconomic status (SES).
METHODS
The study design was a retrospective population-based analysis of the effect of geographic
variation on adherence to NCCN guidelines for treatment of advanced-stage invasive
epithelial ovarian cancer reported to California Cancer Registry using generalized additive
models (GAMs), with simultaneous smoothing of location and adjustment for known
confounders [16, 17]. The study received exempt status by the Institutional Review Board of
the University of California, Irvine (HS#2011-8317). Registry case reporting is estimated to
be 99% for the entire state of California, with follow-up completion rates exceeding 95%
[18]. International Classification of Disease Codes for Oncology based on World Health
Organization's criteria was used for tumor location and histology. Cases were identified
using ovarian Surveillance, Epidemiology, and End Results (SEER) primary site code
(C569).
The initial study population included women who were age ≥18 years at diagnosis of a first
or only invasive epithelial ovarian cancer. A total of 21,044 incident cases were identified
during the time period 1/1/96-12/31/06. We sequentially excluded: 101 borderline tumors,
165 of non-epithelial histology, 246 cases that had missing ICD-O-2 morphology code, 742
cases prepared from autopsy or death certificate only, 1,410 with incomplete clinical
information, 78 with incomplete hospital information or location outside of California, and
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98 with missing census tract information. Among the remaining 18,204 cases of all stages,
11,770 patients diagnosed with International Federation of Gynecology and Obstetrics
(FIGO) stage IIIC/IV disease were selected as the study population and represents a subset
of a prior analysis investigating predictors of access to high-volume providers [11].
The primary analysis was the effect of geographic variation on adherence to NCCN
treatment guidelines for stage IIIC/IV epithelial ovarian cancer based on recommendations
for surgery and chemotherapy according to the time period of diagnosis [19-23]. A
minimum of oophorectomy (with or without hysterectomy) and omentectomy was
considered adherent surgical care, and either initial surgery or chemotherapy was
characterized as appropriate. Administration of multi-agent chemotherapy was characterized
as adherent care. Dichotomous variables, adherence or non-adherence, were created for the
overall treatment program.
The GAM estimates the log odds of NCCN guideline treatment adherence throughout
California by applying a bivariate smooth of the latitude and longitude of participants’
location, represented by the centroid of the address census block. A locally weighted
regression smoother (loess) was used in the analyses. The loess smoother predicts the log
odds by fitting a regression to data points closest to the prediction point and weighting the
data points with a tri-cube function of their distance from the prediction point [24]. The
number of data points used for smoothing was determined by minimizing Akaike's
Information Criterion. An evenly spaced grid of prediction points approximately 5km apart
that extended across the latitude and longitude coordinates of participants’ locations
throughout California was generated, resulting in in a grid of over 13,000 prediction points.
At each point on the grid the log odds and odds ratios were calculated, with the study area
serving as the referent group; the log odds at each point was divided by the log odds from a
reduced model which did not include the smooth of latitude and longitude [16, 17].
GAMs provide a useful framework for hypothesis testing [25]. We used permutation tests to
test the null hypothesis that the odds of adherence to NCCN guidelines was not dependent
on the geographic location of subjects. Residential locations were permuted 999 times while
preserving participants’ outcome status and covariates. For each permutation, the GAM was
refit and a global deviance statistic was computed. If the global statistic indicated that
residential location was a significant predictor of the outcome (p<0.05), point-wise
departures from the null hypothesis using the same set of permutations were evaluated.
Areas of significantly increased or decreased odds were defined as points ranking in the
extreme 2.5% of the distribution of permuted odds ratios at each point. Spatial analyses were
conducted in the R Package (version 2.12.02; Vienna, Austria) using the gam and MapGam
packages. Odds ratios were mapped in ArcMap (version 10.0, ESRI; Redlands, CA) using a
continuous color scheme (dark red to dark blue) and a constant scale range. Areas of
significantly elevated or lowered odds were mapped using black contour bands.
Without the bivariate smooth term, the GAM reduces to an ordinary logistic regression. The
model included age at diagnosis as a continuous variable, tumor characteristics (FIGO stage,
grade, histology and tumor size), insurance type, race, and SES. Insurance type was grouped
into 6 categories: Managed Care (managed care, HMO, PPO, other private insurance),
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Medicare, Medicaid, Other Insurance (military, county-funded), Not Insured (self-pay), and
Unknown. SES was classified according to increasing quintile of Yost score: lowest
(SES-1), low-middle (SES-2), middle (SES-3), high-middle (SES-4) and highest (SES-5)
[18]. The Yost score is an index of SES level based on a principal components analysis of
variables at the census block-level and includes education, household income, proportion
below 200% poverty level, house value, rent, percent employed, and percent with blue-
collar employment [26]. In addition, the model included a variable to indicate if the hospital
for each subject was a high-volume hospital (HVH) or a low-volume hospital (LVH).
Hospital volume was calculated based on the average annual number of all ovarian cancer
cases (stages I-IV) that were admitted in that hospital. Hospitals with ≥20 cases per year
were classified as HVH, and hospitals with <20 cases per year were considered low-volume
[12-15]. Lastly, the model included variables for distance between each subject and the
treating hospital, as well as distance to the closest HVH. Distances were calculated using
ArcMap (version 10.0, ESRI; Redlands, CA) and categorized by quintiles: distance to care
(<5km/3mi; 5-9km/3-5mi; 10-16km/6-9mi; 17-31km/10-19mi; ≥32km/20mi) and distance to
closest HVH (<9km/5mi; 9-17km/5-10mi; 18-33km/11-20mi; 34-79km/21-49mi; ≥80km/
50mi).
Secondary analyses investigated disparities across racial and SES classifications associated
with geographic characteristics identified by the GAM as significantly predictive of
treatment non-adherent to NCCN guidelines. Differences across distance quintiles according
to racial and SES variables were analyzed with the χ2 test for equality of proportions using
the R Package (version 2.12.02; Vienna, Austria).
RESULTS
Population Characteristics
The median age at diagnosis for the 11,770 subjects was 65.0 years (mean=63.8 years,
range=18-104 years), and 7,218 patients (61.3%) had stage IIIC disease (Table 1). The
majority of patients were White (71.7%) followed in frequency by Hispanic (15.3%), Asian/
Pacific Islander (8.3%), and Black (4.7%). Managed Care (44.8%) and Medicare (32.2%)
were the most common payer categories. Overall, 5,343 patients (45.4%) were treated
according to NCCN guidelines (Figure 1A). A total of 378 hospitals provided care to the
study population (Figure 1B). Of these, 12 hospitals (3.2%) were high-volume (2,112
patients, 17.9% of cases) and 366 were low-volume (9,658 patients, 82.1% of cases).
Distances between subject location and the hospital where they received care were
calculated, divided by quintiles, and stratified according to hospital volume. Comparison of
patients treated at HVHs versus those treated at LVHs revealed an inverse relationship for
distance travelled to receive care. Among patients treated at a HVH, the proportion in each
travel distance quintile were: <5km/3mi = 10.8%, 5-9km/3-5mi = 14.1%, 10-16km/6-9mi =
16.4%, 17-31km/10-19mi = 25.1% and ≥32km/20mi = 33.0%. Among patients treated at a
LVH, the proportion in each travel distance quintile were: <5km/3mi = 22.0%, 5-9km/3-5mi
= 21.3%, 10-16km/6-9mi = 20.8%, 17-31km/10-19mi = 18.9%, and ≥32km/20mi = 17.0%).
The differences in distance travelled to receive care according to each quintile were
statistically significant (p<0.0001).
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Spatial Analysis of Adherence to NCCN Guidelines
The initial iteration of the spatial analysis reflects the effect of geographic location on the
likelihood of treatment non-adherent to NCCN guidelines without adjusting for the effects
of other variables and shows the odds of care being non-adherent to NCCN guidelines at
each location relative to the odds for the entire state. The impact of geographic distribution
on treatment adherence to guidelines was affected as additional variables were introduced
into the model in a stepwise fashion (Figure 2). The global test for location was highly
significant for all analyses (p<0.001), indicating that the likelihood of adherence to NCCN
treatment guidelines was significantly associated with the geographic location of subjects.
After controlling for disease-related characteristics, the final model showed that Black race
(OR=1.49, 95%CI=1.21-1.83) and SES were independently associated with an increased
likelihood of treatment non-adherent to NCCN guidelines (Table 2). Compared to the
highest SES group (SES-5), the likelihood of non-standard treatment was increased by 22%
for SES-3, 34% for SES-2, and 46% for SES-1. Treatment at a HVH was significantly
protective (OR=0.59, 95%CI=0.53-0.66). Age, stage, tumor histology, and tumor grade were
also significantly associated with deviation from NCCN guideline care.
The final model also revealed that geographic characteristics were significant predictors of
non-standard treatment after accounting for disease-related and demographic variables.
Patient travel distance to receive care demonstrated a threshold effect, with no statistically
significant difference for travel distances <32km/20mi. However, travel distance to receive
care ≥32km/20mi was associated with an independent and statistically significant protective
effect against treatment that deviated from NCCN guidelines (OR=0.80, 95%CI=0.69-0.92).
A linear trend was observed between increasing distances from a HVH and the likelihood of
treatment deviation from NCCN guidelines, which reached statistical significance at the
threshold of the farthest distance quintile. Specifically, geographic location ≥80km/50mi
from a HVH was independently associated with an increased risk of non-adherent care
(OR=1.88, 95%CI=1.61-2.19).
Race, Socioeconomic Status, and Geographic Predictors of Treatment
The potential interaction between race and SES and the geographic variables predictive of
treatment adherence to NCCN guidelines were explored through a series of contingency
tables and radar plots. Analysis of distance to receive care revealed statistically significant
(p<0.0001) trends across each quintile of distance stratified by racial category (Figure 3A).
The most notable difference was within the longest distance quintile, with a larger
proportion of White patients travelling ≥32km/20mi for care (21.8%) compared to Blacks
(14.4%), Asian/Pacific Islanders (15.9%), and Hispanics (15.5%). Stratification across SES
categories also revealed statistically significant differences for each distance quintile
(p<0.0001). The higher SES groups (SES-4 and SES-5) were more likely to travel
intermediate distances to receive care (5-31km/3-19mi), while the lowest SES group
(SES-1) was the most likely (23.6%) to receive care <5km/3mi from their location of
residence (Figure 3B).
Race was significantly associated with geographic proximity to a HVH across all distance
quintiles (p<0.0001) (Figure 4A). White patients were significantly more likely to live
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≥80km/50mi from a HVH (22.9%) compared to Hispanics (17.8%), Blacks (8.6%), and
Asian/Pacific Islanders (5.2%), while non-White races were more likely to live within
17km/10mi of a HVH. Conversely, Whites were less likely to live within 9km/5mi of a
HVH (17.5%) compared to Hispanics (21.3%), Asian/Pacific Islanders (32.9%) and Blacks
(31.2%). Statistically significant differences were also observed for SES and proximity to a
HVH across all distance quintiles (p<0.0001) (Figure 4B). The most notable difference was
the inverse linear relationship between SES and the proportion of patients living ≥80km/
50mi from a HVH, ranging from 33.0% for the lowest SES group (SES-1) to 6.3% for the
highest SES group (SES-5).
DISCUSSION
The contribution of geography to variation in health care access, utilization, and cancer
survival has generated interest among both health care planners and social epidemiologists
[27]. However, there is limited data examining these relationships for ovarian cancer [28,
29]. In two large studies utilizing the SEER-Medicare database, Polsky et al. and Thrall and
coworkers identified regional variation in both surgery and chemotherapy for ovarian cancer
[30, 31]. While individual patient-level factors were thought to explain much of the
variance, both studies concluded that provider supply could account for many of the
geographic differences. In Canada, Dehaeck et al. reported a population-based study of
ovarian cancer within five health authority regions in the province of British Columbia
demonstrating geographic variation in practice patterns in the context of a single-payer,
publicly funded health care system [32]. Significant differences were observed across
provincial regions for access to a gynecologic oncologist, the rate of optimal debulking, and
administration of combination chemotherapy. There was no significant effect for geography
(health authority region) on survival, however, after adjusting for treatment-related factors.
Such regional differences in health services can point to disparities in access to health care,
and only a handful of studies have addressed this question in ovarian cancer. Fairfield and
coworkers studied 4,589 patients from the SEER database (1998-2002) and found that
hospital referral region was associated with the likelihood of cancer directed surgery but not
chemotherapy use [33]. Hospital referral regions also significantly predicted all-cause
mortality; however, after adjusting for cancer-directed surgery, that correlation was no
longer significant. Non-White race was independently negatively associated with cancer-
directed surgery, chemotherapy use, and all-cause mortality, while income and education
level were not. The authors concluded that improving access to high-quality cancer surgery
might improve outcomes, particularly for minorities and for older women. In a more detailed
analysis of demographic variables, Ulanday and coworkers investigated geographical and
socioeconomic variation in the frequency of lymph node dissection among 5,243 patients
with early-stage ovarian cancer using the SEER database (2000-2008) [34]. These authors
found that after adjusting for demographics, tumor characteristics, and area-based
socioeconomic measures, there was a significant relationship between SEER region and the
frequency of lymph node dissection. In addition to SEER region, older age, Black race,
unemployment, and poverty level were associated with a lower likelihood of lymph node
assessment.
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The current study is unique in several respects. In contrast to previous investigators, we
utilized a composite ovarian cancer quality of care process measure that has been validated
to correlate with disease-specific survival, adherence to NCCN treatment guidelines, rather
than individual treatment components [2, 4]. In addition, the current analysis employed a
GAM to estimate the likelihood of guideline adherence throughout California based on a
grid of over 13,000 geographic prediction points. After controlling for other variables, Black
race, low-SES, and remoteness to a HVH were independently associated with an increased
risk of non-adherent care, while high-volume hospital treatment and farther travel distance
to care were independently protective. We observed significant socio-demographic
disparities within geographic predictors of adherence to treatment guidelines. Increasing
SES was inversely associated with the distance from a HVH, while White patients were
significantly more likely to travel farther to receive care compared to patients of other races.
Strengths of the current study include the large study population size, the proven reliability
of the California Cancer Registry, and examination of a contemporary time period during
which no major treatment paradigm shifts occurred. There are also several limitations that
must be considered when interpreting these data. First, this was a retrospective study design
using a population-based data set and is subject to the inherent potential for reporting and
selection bias that accompanies such methodology. Second, and perhaps most importantly,
we were unable to control for potentially important unreported variables that could influence
both adherence to treatment guidelines as well as referral patterns. Such variables include
the presence of medical comorbidities, the extent of initial disease, patient preferences and
ability to travel, and health care provider bias. A third potential limitation is that the current
dataset utilized de-identified patient data, such that the census block of residence for each
subject was used rather than the exact latitude and longitude of patient residence. It is
possible that the results could be affected by more precise reference points for geographic
location, although it is not possible to predict in which direction the observed associations
might migrate. Finally, we were unable to examine the potential effect of physician
specialty, as the California Cancer Registry does not capture this information routinely, or
physician volume, as multiple site physician practices would confound geographic analysis.
Despite these limitations, several conclusions can be drawn from the current study. First,
these data confirm that race and SES are independently predictive of disparities in adherence
to ovarian cancer treatment guidelines [4-9]. Second, geographic location is associated with
the likelihood of guideline care. Specifically, proximity to a high-volume hospital and travel
distance to receive treatment are independent predictors of NCCN guideline adherent care
for advanced-stage ovarian cancer. Third, geographic barriers to receipt of standard ovarian
cancer treatment disproportionately affect racial minorities and women of low-SES, and
associations between race and SES and geographic risk factors may in part explain
previously observed disparities in survival.
These data are relevant to the national health care landscape, as the demographic dynamic in
California serves as a bellwether for the shift that the country will experience over the next
30 years. Racial minorities, now roughly one-third of the U.S. population, are expected to
become a majority by 2042, a milestone reached in California in 2000 [35, 36]. Additional
research is needed to precisely define the necessary changes in our health care delivery
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system that will optimize work force distribution to underserved populations and facilitate
performance-based concentration of services for all women with ovarian cancer.
Centralization of care for women with ovarian cancer is possible [37]. However, in the
United States, transplant surgery probably offers the best template for how regionalization of
health care services for a relatively uncommon condition that carries a high risk of mortality
without expert care can be successfully implemented. A program for ovarian cancer might
include a national organization providing oversight, regional center designation based on
hospital resources (e.g. intensive care unit, multidisciplinary care and tumor board),
available sub-specialists (e.g. gynecologic oncologist), and minimum hospital and surgeon
annual volume requirements. Center designation would require an active quality
improvement program and participation in a patient registry, with comprehensive reporting
of data on consecutive patients for morbidity, mortality, risk-adjusted quality process
measures (e.g. the proportion of patients receiving NCCN guideline treatment, undergoing
complete cytoreduction, treated neoadjuvant chemotherapy), and cost-effectiveness
benchmarks. Ultimately, performance metrics, including risk-adjusted survival data, would
be available to potential patients, health insurance organizations, and health care
administrators. As for transplant surgery, third party payers would cover care at an approved
center, and resources would be available to patients to facilitate regional referral as well as
coordination of care closer to home. In this way, concentration of services for ovarian cancer
care could be an effective means to reduce disparities in treatment and outcomes and
promote health equity. Ultimately, all people should be afforded the same standard of care,
including access to appropriately qualified surgeons and an optimal treatment setting,
regardless of race, SES, or where they reside [32].
Supplemental material Figure 2 (video): effect of geographic location on risk of non-
adherence to NCCN treatment guidelines for advanced-stage ovarian cancer adjusted for the
effects of other variables.
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(A) Geographic distribution of 11,770 cases of stage IIIC/IV epithelial ovarian cancer
stratified by adherence and non-adherence to NCCN treatment guidelines for advanced-
stage ovarian cancer; (B) Geographic distribution of hospitals stratified by high-volume
(n=12) and low-volume hospital (n=366).
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Effect of geographic location on risk of non-adherence to NCCN treatment guidelines.
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Radar plot: proportional distribution of subject location and distance to receive care quintile
stratified by race (A) and SES category (B). API: Asian/Pacific Islander
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Radar plot: proportional distribution of subject location and distance from a high-volume
hospital quintile stratified by race (A) and SES (B). API: Asian/Pacific Islander
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    <45 1036 8.8
    45-54 2062 17.5
    55-69 4180 35.5
    ≥70 4492 38.2
Race
    White 8433 71.7
    Black 557 4.7
    Hispanic 1804 15.3
    Asian/Pacific Islander 976 8.3
Insurance
    Managed care 5275 44.8
    Medicare 3799 32.3
    Medicaid 941 8.0
    Other insurance 1109 9.4
    Not insured 319 2.7
    Unknown 327 2.8
Socioeconomic status
    Highest (SES-5) 2869 24.4
    Higher-middle (SES-4) 2752 23.4
        Middle (SES-3) 2483 21.1
    Lower-middle (SES-2) 2137 18.2
    Lowest (SES-1) 1529 13.0
Stage
    Stage IIIC 7218 61.3
    Stage IV 4552 38.7
Tumor grade
    Grade 1 344 2.9
    Grade 2 1562 13.3
    Grade 3 4993 42.4
    Grade 4 1240 10.5
    Unknown 3631 30.9
Tumor histology
    Serous 5744 48.8
    Clear cell 321 2.7
    Endometrioid 638 5.4
    Mucinous 415 3.5
    Adenocarcinoma NOS* 1970 16.7
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Characteristic n Percent
    Other 2682 22.8
Tumor size
    <5cm 1274 10.8
    5-10cm 2116 18.0
    ≥0cm 2001 17.0
    Unknown 6379 54.2
Hospital volume
    High volume 2112 17.9
    Low volume 9658 82.1
Treatment guideline adherence
    Adherent 5343 45.4
    Non-adherent 6427 54.6
*
NOS: not otherwise specified
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Table 2
Multivariable analysis of predictors of treatment non-adherent to National Comprehensive Cancer Network
guidelines.
Characteristic Odds ratio 95% Confidence interval
Hospital volume
    Low-volume 1.00 referent
    High-volume 0.59 0.53-0.66
Distance to care
    <5km/3mi 1.00 referent
    5-9km/3-5mi 0.97 0.85-1.10
    10-16km/6-9mi 0.92 0.81-1.05
    17-31km/10-19mi 1.00 0.87-1.14
    ≥32km/20mi 0.80 0.69-0.92
Distance to High-Volume Hospital
    >9km/5mi 1.00 referent
    9-17km/5-10mi 0.96 0.84-1.10
    18-33km/11-20mi 1.05 0.91-1.20
    34-79km/21-49mi 1.12 0.97-1.29
    ≥80km/50mi 1.88 1.61-2.19
Insurance status
    Managed care 1.00 referent
    Medicare 1.10 0.99-1.22
    Medicaid 1.03 0.88-1.21
    Other insurance 1.20 1.04-1.39
    Uninsured 1.11 0.86-1.43
    Unknown 1.26 0.97-1.62
Socioeconomic status
    Highest (SES-5) 1.00 referent
    Higher-middle (SES-4) 1.11 0.98-1.25
    Middle (SES-3) 1.22 1.08-1.39
    Lower-middle (SES-4) 1.34 1.16-1.54
    Lowest (SES-1) 1.46 1.24-1.72
Race
    White 1.00 referent
    Black 1.49 1.21-1.83
    Hispanic 0.97 0.85-1.10
    Asian/Pacific Islander 1.05 0.90-1.22
Age 1.03 1.03-1.04
Stage
    Stage IIIC 1.00 referent
    Stage IV 1.59 1.46-1.73
Tumor grade
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Characteristic Odds ratio 95% Confidence interval
    Grade 1 1.41 1.11-1.80
    Grade 2 1.22 1.08-1.38
    Grade 3 1.00 referent
    Grade 4 1.03 0.90-1.18
    Unknown 2.99 2.69-3.33
Tumor histology
    Serous 1.00 referent
    Clear cell 1.20 0.94-1.53
    Endometrioid 1.36 1.14-1.62
    Mucinous 1.73 1.38-2.17
    Adenocarcinoma NOS* 3.14 2.75-3.58
    Other 2.07 1.85-2.30
*
NOS: not otherwise specified
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